Coeptis Therapeutics, Inc., a biopharmaceutical company, develops and commercializes generic and branded pharmaceutical products and cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a Vy-Gen drug product for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; and CD38-Diagnostic, an in vitro screening tool to provide the ability to pre-determine which cancer patients are most likely to benefit from targeted anti-CD38 monoclonal antibodies therapies. The company has collaboration with Statera BioPharma to develop and commercialize STAT-201 for Crohn's disease; and Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. Coeptis Therapeutics, Inc. was founded in 2017 and is headquartered in Wexford, Pennsylvania.
The current price of COEP.BOATS is $10.87 USD — it has increased by +0% in the past 24 hours. Watch Coeptis Therapeutics stock price performance more closely on the chart.
What is Coeptis Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Coeptis Therapeutics stocks are traded under the ticker COEP.BOATS.
When is the next Coeptis Therapeutics earnings date?▼
Coeptis Therapeutics is going to release the next earnings report on June 03, 2026.
When did Coeptis Therapeutics complete a stock split?▼
Coeptis Therapeutics has not had any recent stock splits.